Cargando…
CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malignancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is transfer of natural or engineered tumor-specific T-cells into patients, a so called “...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493839/ https://www.ncbi.nlm.nih.gov/pubmed/32973401 http://dx.doi.org/10.1186/s12935-020-01546-8 |